Fraunhofer-Institut für Zelltherapie und Immunologie IZI
Fraunhofer-Institut für Zelltherapie und Immunologie IZI

Präklinische Validierung

Publikationen

  • Eberlein V, Rosencrantz S, Finkensieper J, Besecke JK, Mansuroglu Y, Kamp JC, Lange F, Dressman J, Schopf S, Hesse C, Thoma M, Fertey J, Ulbert S, Grunwald T. Mucosal immunization with a low-energy electron inactivated respiratory syncytial virus vaccine protects mice without Th2 immune bias. Front Immunol. 2024 Apr 5:15:1382318. doi: 10.3389/fimmu.2024.1382318. eCollection 2024.
  • Funk C, Uhlig N, Ruzsics Z, Baur F, Peindl M, Nietzer S, Epting K, Vacun G, Dandekar G, Botteron C, Werno C, Grunwald T, Bailer SM. TheraVision: Engineering platform technology for the development of oncolytic viruses based on herpes simplex virus type 1. Mol Ther Oncol. 2024 Feb 28;32(1):200784. doi: 10.1016/j.omton.2024.200784. eCollection 2024 Mar 21.
  • Ciulean I S, Fischer J, Quaiser A, Bach C, Abken H, Tretbar U S, Fricke S, Köhl U, Schmiedel D, Grunwald T. CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma. Front Immunol 2023, 14: 1290488. doi: 10.3389/fimmu.2023.1290488
  • Eberlein V, Ahrends M, Bayer L, Finkensieper J, Besecke J K, Mansuroglu Y, Standfest B, Lange F, Schopf S, Thoma M, Dressman J, Hesse C, Ulbert S, Grunwald T. Mucosal application of a low-energy electron inactivated respiratory syncytial virus vaccine shows protective efficacy in an animal model. Viruses 2023, 15 (9), article 1846. doi: 10.3390/v15091846
  • Issmail L, Ramsbeck D, Jäger C, Henning T, Kleinschmidt M, Buchholz M, Grunwald T. Identification and evaluation of a novel tribenzamide derivative as an inhibitor targeting the entry of the respiratory syncytial Virus. Antiviral Res. 2023 Mar:211:105547. doi: 10.1016/j.antiviral.2023.105547. Epub 2023 Jan 20.
  • Mötzing M, Blüher M, Grunwald T, Hoffmann R. Immunological quantitation of the glycation site Lysine‐414 in serum albumin in human plasma samples by indirect ELISA using highly specific monoclonal antibodies. Chembiochem. 2024 Feb 16;25(4):e202300550. doi: 10.1002/cbic.202300550. Epub 2023 Nov 9.
  • Reus P, Guthmann H, Uhlig N, Agbaria M, Issmail L, Eberlein V, Nordling-David MM, Jbara-Agbaria D, Ciesek S, Bojkova D, Cinatl J, Burger-Kentischer A, Rupp S, Zaliani A, Grunwald T, Gribbon P, Kannt A, Golomb G. Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system. J Control Release 2023, 364: 654-671. doi: 10.1016/j.jconrel.2023.10.050
  • Weiß R, Issmail L, Rockstroh A, Grunwald T, Fertey J, Ulbert S. Immunization with different recombinant West Nile virus envelope proteins induces varying levels of serological cross-reactivity and protection from infection. Front Cell Infect Microbiol, 2023, 13: 1279147. doi: 10.3389/fcimb.2023.1279147
  • Finkensieper J, Issmail L, Fertey J, Rockstroh A, Schopf S, Standfest B, Thoma M, Grunwald T, Ulbert S. Low-energy electron irradiation of tick-borne encephalitis virus provides a protective inactivated vaccine. Front Immunol. 2022 Mar 7;13:825702. doi: 10.3389/fimmu.2022.825702. eCollection 2022 
  • Groß R, Lívia Mesquita D L, Issmail L, Uhlig N, Eberlein V, Conzelmann C, Olari L-R, Rauch L, Lawrenz J, Weil T, Mueller J A, Cardoso M B, Gilg A, Larrson O, Hoeglund U, Axberg Pålsson, Tvilum A S, Løvschall K B, Kristensen M M, Spetz A-L, Hontonnou F, Galloux M, Zelikin A N, Grunwald T, Muench J. Macromolecular viral entry inhibitors as broad‐spectrum first‐line antivirals with activity against SARS‐CoV‐2. Adv Sci (Weinh). 2022 Jul;9(20):e2201378. doi: 10.1002/advs.202201378. Epub 2022 May 11 
  • Issmail L, Möser C, Jäger C, Altattan B, Ramsbeck D, Kleinschmidt M, Buchholz M, Smith D, Grunwald T. Prefusion-specific antibody-derived peptides trivalently presented on DNA-nanoscaffolds as an innovative strategy against RSV entry. Frontiers in Virology (2022). doi: 10.3389/fviro.2022.994843
  • Peter A S, Roth E, Schulz S R, Fraedrich K, Steinmetz T, Damm D, Hauke M, Richel E, Mueller-Schmucker S, Habenicht K, Eberlein V, Issmail L, Uhlig N, Dolles S, Gruener E, Peterhoff D, Ciesek S, Hoffmann M H, Poehlmann S, McKay P F, Shattock R J, Woelfel R, Socher E, Wagner R, Eichler J, Sticht H, Schuh W, Neipel F, Ensser A, Mielenz D, Tenbusch M, Winkler T H, Grunwald T, Überla K, Jäck H-M. A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. Eur J Immunol. 2022 May;52(5):770-783. doi: 10.1002/eji.202149374. Epub 2021 Sep 13 
  • Stegmann K M, Dickmanns A, Heinen N, Blaurock C, Karrasch T, Breithaupt A, Klopffleisch R, Uhlig N, Eberlein V, Issmail L, Herrmann S T, Schreieck A, Peelen E, Kohlhof H, Sadeghi B, Riek A, Speakman J R, Groß U, Goerlich D, Vitt D, Mueller T, Grunwald T, Pfaender S, Balkema-Buschmann A, Dobbelstein M. Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication. iScience. 2022 May 20;25(5):104293. doi: 10.1016/j.isci.2022.104293. Epub 2022 Apr 25 
  • Weil T, Kirupakaran A, Le M-H, Rebmann P, Mieres-Perez J, Issmail L, Conzelmann C, Mueller J A, Rauch L, Gilg A, Wettstein L, Groß R, Read C, Bergner T, Axberg Pålsson S, Uhlig N, Eberlein V, Woell H, Klaerner F-G, Stenger S, Kuemmerer B M, Streeck H, Fois G, Frick M, Braubach P, Spetz A-L, Grunwald T, Shorter J, Sanchez-Garcia E, Schrader T, Muench J. Advanced molecular tweezers with lipid anchors against SARS-CoV-2 and other respiratory viruses. JACS Au. 2022 Sep 6;2(9):2187-2202. doi: 10.1021/jacsau.2c00220. eCollection 2022 Sep 26 
  • Gege C, Bravo F J.; Uhlig N, Hagmaier T, Schmachtenberg R, Elis J, Burger-Kentischer A, Finkelmeier D, Hamprecht K, Grunwald T, Bernstein D I, Kleymann G. A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections. Sci Transl Med. 13 (2021), 598, eabf8668. doi: 10.1126/scitranslmed.abf8668
  • Hoyer S, Eberlein V, Schuler G, Berking C, Heinzerling L, Schaft N, Dörrie J. BRAF and MEK inhibitors affect dendritic-cell maturation and t-cell stimulation. Int J Mol Sci. 22 (2021), 21, 11951. doi: 10.3390/ijms222111951
  • Lapuente D, Fuchs J, Willar J, Antão AV, Eberlein V, Uhlig N, Issmail L, Schmidt A, Oltmanns F, Peter AS,Mueller-Schmucker S, Irrgang P, Fraedrich K, Cara A, Hoffmann M, Pöhlmann S, Ensser A, Pertl C, Willert T, Thirion C, Grunwald T, Überla K, Tenbusch M. Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nat Commun. (2021), 12, 1, 6871. doi: 10.1038/s41467-021-27063-4
  • Peter AS, Roth E, Schulz SR, Fraedrich K, Steinmetz T, Damm D, Hauke M, Richel E, Mueller-Schmucker S, Habenicht K, Eberlein V, Issmail L, Uhlig N, Dolles S, Grüner E, Peterhoff D, Ciesek S, Hoffmann M, Pöhlmann S, McKay PF, Shattock RJ, Wölfel R, Socher E, Wagner R, Eichler J, Sticht H, Schuh W, Neipel F, Ensser A, Mielenz D, Tenbusch M, Winkler TH, Grunwald T, Überla K, Jäck H-M. A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. Eur J Immunol. (2021), Aug 6. doi: 10.1002/eji.202149374
  • Uhlig N, Donner A-K, Gege C, Lange F, Kleymann G, Grunwald T. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model. Antiviral Res. (2021), 195, 105190. doi: 10.1016/j.antiviral.2021.105190
  • Berneck BS, Rockstroh A, Fertey J, Grunwald T, Ulbert S. A recombinant zika virus envelope protein with mutations in the conserved fusion loop leads to reduced antibody cross-reactivity upon vaccination. Vaccines 8 (2020) 4, Artikel-Nr.: 603, 10 Seiten. dx.doi.org/10.3390/vaccines8040603
  • Fertey J, Thoma M, Beckmann J, Finkensieper J, Reißhauer S, Berneck BS, Issmail L, Schönfelder J, Casado JP, Poremba A, Rögner F-H, Standfest B, Makert GR, Walcher L, Kistenmacher A-K, Fricke S, Grunwald T, Ulbert S, Bayer L. Automated application of low energy electron irradiation enables inactivation of pathogen- and cell-containing liquids in biomedical research and production facilities. Scientific reports 10 (2020) 1, Artikel-Nr.: 12786, 14 Seiten. dx.doi.org/10.1038/s41598-020-69347-7
  • Kähl S, Volke D, Fornefett J, Fingas F, Klose K, Benga L, Grunwald T, Ulrich R, Hoffmann R, Baums CG. Identification of a large repetitive RTX immunogen in a highly virulent Rodentibacter heylii strain. Microbes and Infection 23 (2020), S1286-4579(20)30185-4. dx.doi.org/10.1016/j.micinf.2020.10.007
  • Wilmschen S, Schneider S, Peters F, Bayer L, Issmail L, Bánki Z, Grunwald T, von Laer D, Kimpel J. RSV vaccine based on rhabdoviral vector protects after single. Vaccines 7 (2019), 3, article 59, 17 Seiten, dx.doi.org/10.3390/vaccines7030059
  • Bayer L, Fertey J, Ulbert S, Grunwald T. Immunization with an adjuvanted low-energy electron irradiation inactivated respiratory syncytial virus vaccine shows immunoprotective activity in mice. Vaccine 36 (2018), 12, S. 1561-1569. dx.doi.org/10.1016/j.vaccine.2018.02.014
  • Bayer L, Gümpel J, Hause G, Müller M, Grunwald T. Non-human papillomaviruses for gene delivery in vitro and in vivo. PLoS one 13 (2018), Art. e0198996, 14 S. dx.doi.org/10.1371/journal.pone.0198996
  • Fingas F, Rückner A, Heenemann K, Volke D, Sieg M, Bielefeldt P, Grunwald T, Vahlenkamp TW, Hassert R, Hoffmann R. Highly sensitive ELISA for the serological detection of murine rotavirus EDIM based on its major immunogen VP6. Journal of Virological Methods 262 (2018), S. 72-78. dx.doi.org/10.1016/j.jviromet.2018.07.016
  • Fornefett J, Krause J, Klose K, Fingas F, Hassert R, Benga L, Grunwald T, Müller U, Schrödl W, Baums CG. Comparative analysis of humoral immune responses and pathologies of BALB/c and C57BL/6 wildtype mice experimentally infected with a highly virulent Rodenti­bacter pneumotropicus (Pasteurella pneumotropica) strain. BMC microbiology 18 (2018), Article 45, 11 S. dx.doi.org/10.1186/s12866-018-1186-8
  • Fornefett J, Krause J, Klose K, Fingas F, Hassert R, Eisenberg T, Schrödl W, Grunwald T, Müller U, Baums CG. Comparative analysis of clinics, pathologies and immune responses in BALB/c and C57BL/6 mice infected with Streptobacillus moniliformis. Microbes and infection 20 (2018), 2, S. 101-110. dx.doi.org/10.1016/j.micinf.2017.10.001
  • Ambrosius B, Faissner S, Guse K, von Lehe M, Grunwald T, Gold R, Grewe B, Chan A. Teriflunomide and mono-methylfumarate target HIV-induced neuro-inflammation and neurotoxicity. Journal of neuroinflammation 14 (2017), Art. 51, 10 S. dx.doi.org/10.1186/s12974-017-0829-2
  • Fornefett J, Krause J, Klose K, Fingas F, Hassert R, Eisenberg T, Schrödl W, Grunwald T, Müller U, Baums CG. Comparative analysis of clinics, pathologies and immune responses in BALB/c and C57BL/6 mice infected with Streptobacillus moniliformis. Microbes and infection. 20 (2018), 2, S. 101-110. dx.doi.org/10.1016/j.micinf.2017.10.001
  • Haid S, Grethe C, Bankwitz D, Grunwald T, Pietschmann T. Identification of a human respiratory syncytial virus cell entry inhibitor by using a novel lentiviral pseudotype system. Journal of virology. 90 (2016), Nr. 6, S. 3065-3073. dx.doi.org/10.1128/JVI.03074-15
  • Grunwald T, Ulbert S. Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases. Clin Exp Vaccine Res. 2015 Jan;4(1):1-10. DOI http://dx.doi.org/10.7774/cevr.2015.4.1.1
  • Faissner S, Ambrosius B, Schanzmann K, Grewe B, Potthoff A, Münch J, Sure U, Gramberg T, Wittmann S, Brockmeyer N, Uberla K, Gold R, Grunwald T, Chan A. Cytoplasmic HIV-RNA in monocytes determines microglial activation and neuronal cell death in HIV-associated neurodegeneration. Exp Neurol. 2014 Nov;261:685-97. DOI http://dx.doi.org/10.1016/j.expneurol.2014.08.011
  • Grunwald T, Tenbusch M, Schulte R, Raue K, Wolf H, Hannaman D, de Swart RL, Uberla K, Stahl-Hennig C. Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates. J Virol. 2014 Apr;88(8):3997-4007. DOI http://dx.doi.org/10.1128/JVI.02736-13
  • Sharma A, Wendland R, Sung B, Wu W, Grunwald T, Worgall S. Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection. Vaccine. 2014 Sep 29;32(43):5761-8. DOI http://dx.doi.org/10.1016/j.vaccine.2014.08.049
  • Lai D, Odimegwu DC, Esimone C, Grunwald T, Proksch P. Phenolic compounds with in vitro activity against respiratory syncytial virus from the Nigerian lichen Ramalina farinacea. Planta Med. 2013 Oct;79(15):1440-6. DOI http://dx.doi.org/10.1055/s-0033-1350711
  • Pachernegg S, Joshi I, Muth-Köhne E, Pahl S, Münster Y, Terhag J, Karus M, Werner M, Ma-Högemeier ZL, Körber C, Grunwald T, Faissner A, Wiese S, Hollmann M. Undifferentiated embryonic stem cells express ionotropic glutamate receptor mRNAs. Front Cell Neurosci. 2013 Dec 3;7:241. DOI http://dx.doi.org/10.3389/fncel.2013.00241
  • Stab V, Nitsche S, Niezold T, Storcksdieck Genannt Bonsmann M, Wiechers A, Tippler B, Hannaman D, Ehrhardt C, Uberla K, Grunwald T, Tenbusch M. Protective efficacy and immunogenicity of a combinatory DNA vaccine against Influenza A Virus and the Respiratory Syncytial Virus. PLoS One. 2013 Aug 14;8(8):e72217. DOI http://dx.doi.org/10.1371/journal.pone.0072217
  • Décard BF, von Ahsen N, Grunwald T, Streit F, Stroet A, Niggemeier P, Schottstedt V, Riggert J, Gold R, Chan A. Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012 Dec;83(12):1170-3. DOI http://dx.doi.org/10.1136/jnnp-2012-303068
  • Grewe B, Hoffmann B, Ohs I, Blissenbach M, Brandt S, Tippler B, Grunwald T, Uberla K. Cytoplasmic utilization of human immunodeficiency virus type 1 genomic RNA is not dependent on a nuclear interaction with gag. J Virol. 2012 Mar;86(6):2990-3002. DOI http://dx.doi.org/10.1128/JVI.06874-11
  • Schneeweiss A, Chabierski S, Salomo M, Delaroque N, Al-Robaiy S, Grunwald T, Bürki K, Liebert UG, Ulbert S. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII. Vaccine. 2011 Aug 26;29(37):6352-7. DOI http://dx.doi.org/10.1016/j.vaccine.2011.04.116
  • Tenbusch M, Grunwald T, Niezold T, Storcksdieck Genannt Bonsmann M, Hannaman D, Norley S, Uberla K. Codon-optimization of the hemagglutinin gene from the novel swine origin H1N1 influenza virus has differential effects on CD4(+) T-cell responses and immune effector mechanisms following DNA electroporation in mice. Vaccine. 2010 Apr 26;28(19):3273-7. DOI http://dx.doi.org/10.1016/j.vaccine.2010.02.090
  • Esimone CO, Grunwald T, Nworu CS, Kuate S, Proksch P, Uberla K. Broad spectrum antiviral fractions from the lichen Ramalina farinacea (L.) Ach. Chemotherapy. 2009;55(2):119-26. DOI http://dx.doi.org/10.1159/000194974
  • Kohlmann R, Schwannecke S, Tippler B, Ternette N, Temchura VV, Tenbusch M, Uberla K, Grunwald T. Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J Virol. 2009 Dec;83(23):12601-10. DOI http://dx.doi.org/10.1128/JVI.01036-09
  • Potthoff A, Schwannecke S, Nabi G, Hoffmann D, Grunwald T, Wildner O, Brockmeyer NH, Uberla K, Tenbusch M. Immunogenicity and efficacy of intradermal tattoo immunization with adenoviral vector vaccines. Vaccine. 2009 May 11;27(21):2768-74. DOI http://dx.doi.org/10.1016/j.vaccine.2009.03.001
  • Röhrs S, Kutzner N, Vlad A, Grunwald T, Ziegler S, Müller O. Chronological expression of Wnt target genes Ccnd1, Myc, Cdkn1a, Tfrc, Plf1 and Ramp3. Cell Biol Int. 2009 Apr;33(4):501-8. DOI http://dx.doi.org/10.1016/j.cellbi.2009.01.016
  • Stang A, Petrasch-Parwez E, Brandt S, Dermietzel R, Meyer HE, Stühler K, Liffers ST, Uberla K, Grunwald T. Unintended spread of a biosafety level 2 recombinant retrovirus. Retrovirology. 2009 Sep 22;6:86. DOI http://dx.doi.org/10.1186/1742-4690-6-86
  • Eckardt-Michel J, Lorek M, Baxmann D, Grunwald T, Keil GM, Zimmer G. The fusion protein of respiratory syncytial virus triggers p53-dependent apoptosis. J Virol. 2008 Apr;82(7):3236-49. DOI http://dx.doi.org/10.1128/JVI.01887-07
  • Esimone CO, Eck G, Duong TN, Uberla K, Proksch P, Grunwald T. Potential anti-respiratory syncytial virus lead compounds from Aglaia species. Pharmazie. 2008 Oct;63(10):768-73.
  • Brandt S, Blissenbach M, Grewe B, Konietzny R, Grunwald T, Uberla K. Rev proteins of human and simian immunodeficiency virus enhance RNA encapsidation. PLoS Pathog. 2007 Apr;3(4):e54.
  • Neuhoff S, Moers J, Rieks M, Grunwald T, Jensen A, Dermietzel R, Meier C. Proliferation, differentiation, and cytokine secretion of human umbilical cord blood-derived mononuclear cells in vitro. Exp Hematol. 2007 Jul;35(7):1119-31.
  • Ternette N, Stefanou D, Kuate S, Uberla K, Grunwald T. Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps. Virol J. 2007 Jun 5;4:51.
  • Ternette N, Tippler B, Uberla K, Grunwald T. Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus. Vaccine. 2007 Oct 10;25(41):7271-9.
  • Brandt S, Grunwald T, Lucke S, Stang A, Uberla K. Functional replacement of the R region of simian immunodeficiency virus-based vectors by heterologous elements. J Gen Virol. 2006 Aug;87(Pt 8):2297-307.
  • Jogler C, Hoffmann D, Theegarten D, Grunwald T, Uberla K, Wildner O. Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. J Virol. 2006 Apr;80(7):3549-58.
  • Quack I, Rump LC, Gerke P, Walther I, Vinke T, Vonend O, Grunwald T, Sellin L. beta-Arrestin2 mediates nephrin endocytosis and impairs slit diaphragm integrity. Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14110-5.
  • Esimone CO, Grunwald T, Wildner O, Nchinda G, Tippler B, Proksch P, Uberla K. In vitro pharmacodynamic evaluation of antiviral medicinal plants using a vector-based assay technique. J Appl Microbiol. 2005;99(6):1346-55.
  • Lucke S, Grunwald T, Uberla K. Reduced mobilization of Rev-responsive element-deficient lentiviral vectors. J Virol. 2005 Jul;79(14):9359-62.
  • Grunwald T, Pedersen FS, Wagner R, Uberla K. Reducing mobilization of simian immunodeficiency virus based vectors by primer complementation. J Gene Med. 2004 Feb;6(2):147-54.